Adimmune Corporation (4142.TW)
TWD 18.4
(1.38%)
TWD 18.4
(1.38%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.48 Billion TWD | 3.67% |
| 2022 | 9.14 Billion TWD | 14.21% |
| 2021 | 8.01 Billion TWD | -5.47% |
| 2020 | 8.47 Billion TWD | 28.97% |
| 2019 | 6.57 Billion TWD | 15.71% |
| 2018 | 5.67 Billion TWD | -1.18% |
| 2017 | 5.74 Billion TWD | -15.31% |
| 2016 | 6.78 Billion TWD | 24.85% |
| 2015 | 5.43 Billion TWD | -7.21% |
| 2014 | 5.85 Billion TWD | 6.75% |
| 2013 | 5.48 Billion TWD | -8.46% |
| 2012 | 5.99 Billion TWD | 6.87% |
| 2011 | 5.6 Billion TWD | 3.53% |
| 2010 | 5.41 Billion TWD | -5.11% |
| 2009 | 5.7 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 8.71 Billion TWD | -6.83% |
| 2024 Q1 | 9.35 Billion TWD | -1.34% |
| 2023 Q2 | 9.2 Billion TWD | 0.99% |
| 2023 Q4 | 9.48 Billion TWD | 2.16% |
| 2023 Q1 | 9.11 Billion TWD | -0.34% |
| 2023 FY | 9.48 Billion TWD | 3.67% |
| 2023 Q3 | 9.28 Billion TWD | 0.84% |
| 2022 Q3 | 9.21 Billion TWD | 4.17% |
| 2022 FY | 9.14 Billion TWD | 14.21% |
| 2022 Q1 | 8.02 Billion TWD | 0.24% |
| 2022 Q2 | 8.84 Billion TWD | 10.14% |
| 2022 Q4 | 9.14 Billion TWD | -0.7% |
| 2021 FY | 8.01 Billion TWD | -5.47% |
| 2021 Q3 | 8.12 Billion TWD | -1.91% |
| 2021 Q4 | 8.01 Billion TWD | -1.43% |
| 2021 Q2 | 8.28 Billion TWD | -0.66% |
| 2021 Q1 | 8.33 Billion TWD | -1.59% |
| 2020 Q2 | 6.8 Billion TWD | 1.68% |
| 2020 Q3 | 6.82 Billion TWD | 0.22% |
| 2020 Q4 | 8.47 Billion TWD | 24.21% |
| 2020 FY | 8.47 Billion TWD | 28.97% |
| 2020 Q1 | 6.69 Billion TWD | 1.89% |
| 2019 Q1 | 5.35 Billion TWD | -5.63% |
| 2019 Q2 | 7.2 Billion TWD | 34.52% |
| 2019 Q3 | 6.77 Billion TWD | -6.07% |
| 2019 FY | 6.57 Billion TWD | 15.71% |
| 2019 Q4 | 6.57 Billion TWD | -2.96% |
| 2018 Q4 | 5.67 Billion TWD | -0.78% |
| 2018 FY | 5.67 Billion TWD | -1.18% |
| 2018 Q1 | 5.7 Billion TWD | -0.67% |
| 2018 Q2 | 5.73 Billion TWD | 0.57% |
| 2018 Q3 | 5.72 Billion TWD | -0.29% |
| 2017 Q2 | 6.17 Billion TWD | -5.0% |
| 2017 Q1 | 6.5 Billion TWD | -4.16% |
| 2017 FY | 5.74 Billion TWD | -15.31% |
| 2017 Q4 | 5.74 Billion TWD | -3.13% |
| 2017 Q3 | 5.93 Billion TWD | -3.98% |
| 2016 FY | 6.78 Billion TWD | 24.85% |
| 2016 Q4 | 6.78 Billion TWD | 21.02% |
| 2016 Q3 | 5.6 Billion TWD | 1.75% |
| 2016 Q2 | 5.51 Billion TWD | 4.88% |
| 2016 Q1 | 5.25 Billion TWD | -3.32% |
| 2015 Q2 | 5.82 Billion TWD | 1.99% |
| 2015 Q3 | 5.58 Billion TWD | -4.06% |
| 2015 FY | 5.43 Billion TWD | -7.21% |
| 2015 Q4 | 5.43 Billion TWD | -2.77% |
| 2015 Q1 | 5.71 Billion TWD | -2.46% |
| 2014 Q1 | 5.78 Billion TWD | 5.44% |
| 2014 FY | 5.85 Billion TWD | 6.75% |
| 2014 Q4 | 5.85 Billion TWD | -12.64% |
| 2014 Q2 | 5.87 Billion TWD | 1.6% |
| 2014 Q3 | 6.7 Billion TWD | 14.07% |
| 2013 Q2 | 5.79 Billion TWD | -1.62% |
| 2013 Q4 | 5.48 Billion TWD | -2.95% |
| 2013 FY | 5.48 Billion TWD | -8.46% |
| 2013 Q1 | 5.89 Billion TWD | -1.64% |
| 2013 Q3 | 5.65 Billion TWD | -2.53% |
| 2012 Q4 | 5.99 Billion TWD | -2.8% |
| 2012 Q3 | 6.16 Billion TWD | -0.96% |
| 2012 Q1 | 5.64 Billion TWD | 0.57% |
| 2012 FY | 5.99 Billion TWD | 6.87% |
| 2012 Q2 | 6.22 Billion TWD | 10.38% |
| 2011 Q4 | 5.6 Billion TWD | -0.11% |
| 2011 Q2 | 5.33 Billion TWD | 0.0% |
| 2011 Q3 | 5.61 Billion TWD | 5.2% |
| 2011 FY | 5.6 Billion TWD | 3.53% |
| 2010 FY | 5.41 Billion TWD | -5.11% |
| 2010 Q4 | 5.41 Billion TWD | 0.0% |
| 2009 FY | 5.7 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Apex Biotechnology Corp. | 2.29 Billion TWD | -312.905% |
| Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | -51.725% |
| Panion & Bf Biotech Inc. | 3.23 Billion TWD | -193.166% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | -83.393% |
| GenMont Biotech Incorporation | 1.65 Billion TWD | -473.708% |
| Abnova (Taiwan) Corporation | 1.35 Billion TWD | -599.575% |
| Tanvex BioPharma, Inc. | 2.76 Billion TWD | -243.216% |
| Polaris Group | 9.09 Billion TWD | -4.248% |
| Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | -1044.676% |
| UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -1282.714% |
| PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | -568.787% |